TG Therapeutics Inc. (TGTX)

7.74
NASDAQ : Health Technology
Prev Close 7.97
Day Low/High 7.74 / 7.98
52 Wk Low/High 3.32 / 12.90
Avg Volume 1.48M
Exchange NASDAQ
Shares Outstanding 90.83M
Market Cap 723.95M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Celebrating the Greatness of Individual Traders

Celebrating the Greatness of Individual Traders

Good individual traders will produce returns far in excess of anything that traditional Wall Street will earn.

3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'

3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'

Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

The Machines Are Sapping the Fun out of This Day

The Machines Are Sapping the Fun out of This Day

Historically, the day before a holiday often has a positive bias, but the algos have killed emotion.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Shark Bites: There Wasn't Even a Dip to Buy

Shark Bites: There Wasn't Even a Dip to Buy

Action runs counter to pattern, leaving market players wondering what to do.

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

We'll see what happens in the way of reaction to Trump's tax policy this afternoon, but if we sell off I'm likely going to be a buyer.

Desire to Add Exposure Leads Indices Higher

Desire to Add Exposure Leads Indices Higher

The fact that many traders weren't well-positioned for Monday's move up is helping to create one-way action this morning.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

2 Biotechs to Watch Ahead of the Election

2 Biotechs to Watch Ahead of the Election

These 2 small-caps have strong pipelines and are becoming analyst darlings.

TG Therapeutics Looks Like a Healthy Play

TG Therapeutics Looks Like a Healthy Play

Small biotech tanked on weak earnings, but still seems promising.

5 Small-Cap Favorites Are Moving on Up

5 Small-Cap Favorites Are Moving on Up

Updates on smaller housing, retail and biotech plays recently mentioned on these pages.

Profiting on Small-Cap Biotech Earnings

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.

Are Drug Stocks What's Ailing the Market?

This move in health care takes your breath away.

Market Closes Back Where It Started

Greece provides good news, but bulk of action wasn't intraday.

More Morning Musings

It appears based on the futures that the market's rally will continue today, at least at the open. Personally, I think investors are becoming complacent given what could unfold in Greece over the next week. Everyone seems to be betting that Europe w...

3 Biotechs That Are Worth Buying

Many of these stocks are off to the races.

Cramer: Bob Dylan Was Right

The answer is blowing in the currency headwind.

A Textbook V-Shaped Bounce

Going against the bulls this time would be a very risky bet.

Momentum Is Not Dead

The chasing in certain areas was intense.

Action Was Ugly, But Healthy

If the market gaps down in the morning, watch for the dip buyers.

Stick a Fork in 2014

We get a fresh start on Friday.

Some Holiday Cheer

Biotechnology stocks see a very strong bounce.